Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Bristol-Myers Squibb Co., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data reveals notable fluctuations over the five-year period under review. Net operating profit after taxes (NOPAT) demonstrates considerable variability, with a negative value of -6,822 million US dollars in 2020, turning positive to 6,656 million in 2021, then declining to 4,571 million in 2022. A recovery is observed in 2023 with 5,869 million, followed by a substantial decline to -9,292 million in 2024. This pattern suggests significant volatility in operating performance.

The cost of capital shows a moderate upward trend from 7.19% in 2020 to a peak of 7.93% in 2022. A slight reduction occurs thereafter, stabilizing around 7.45-7.49% in 2023 and 2024. This relatively stable cost of capital indicates minor variations in the company’s risk profile or capital structure over the period.

Invested capital exhibits a consistent downward trend, decreasing from 90,149 million US dollars in 2020 to 62,654 million in 2024. This reduction in invested capital might reflect divestitures, asset sales, efficiency improvements, or a strategic shift in asset management.

Economic profit mirrors the volatility seen in NOPAT but with notably larger negative values in 2020 and 2024 (-13,301 million and -13,985 million, respectively). Positive economic profits are recorded only in 2021 (611 million) and 2023 (834 million), with negative values in 2022 (-1,119 million). This suggests that, despite periods of operational profitability, the company has struggled to consistently generate returns above its cost of capital, resulting in value destruction in most years.

Overall, the data indicates a company experiencing significant operational and economic performance volatility, with decreasing capital investment and periods of both profitability and value erosion.


Net Operating Profit after Taxes (NOPAT)

Bristol-Myers Squibb Co., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings (loss) attributable to BMS
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for expected credit loss2
Increase (decrease) in restructuring liability3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for expected credit loss.

3 Addition of increase (decrease) in restructuring liability.

4 Addition of increase (decrease) in equity equivalents to net earnings (loss) attributable to BMS.

5 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net earnings (loss) attributable to BMS.

8 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Earnings (Loss) Attributable to BMS
The net earnings exhibit significant volatility over the five-year period. In 2020, the company experienced a substantial loss of approximately $9.015 billion. This was followed by a strong recovery in 2021, with net earnings turning positive at around $6.994 billion. The positive trend continued through 2022 and 2023, with earnings of $6.327 billion and $8.025 billion, respectively, indicating operational improvements and profitability restoration. However, in 2024, the net earnings again declined sharply to a loss of about $8.948 billion, suggesting potential one-time charges, operational challenges, or market conditions adversely affecting profitability.
Net Operating Profit After Taxes (NOPAT)
The NOPAT values reflect a similar pattern of volatility as net earnings. In 2020, the company reported a significant negative NOPAT of approximately $6.822 billion. The following year showed a substantial positive turnaround with NOPAT reaching $6.656 billion. Despite this improvement, the subsequent years showed a decline in NOPAT, falling to $4.571 billion in 2022 and recovering slightly to $5.869 billion in 2023. In 2024, there was a notable decline to a negative $9.292 billion, aligning with the net earnings loss. This suggests that operational efficiency and tax impacts fluctuated considerably, with a sharp deterioration in 2024 likely driven by operational issues or exceptional expenses.
Overall Trend and Insights
Both net earnings and NOPAT demonstrate a pronounced cyclical pattern, with strong losses in 2020 followed by recovery in the subsequent years up to 2023, and then a substantial reversal back to losses in 2024. This pattern indicates that while the company was able to restore profitability after a difficult 2020, it encountered renewed challenges in 2024. The divergence between earnings and operating profit in some years suggests that non-operating factors, such as extraordinary items or tax effects, may have influenced net profitability. The data points to the necessity for a deeper review of underlying causes behind the 2024 downturn, including potential one-time charges, market dynamics, or changes in operational efficiency.

Cash Operating Taxes

Bristol-Myers Squibb Co., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Provision
The income tax provision shows a fluctuating trend over the five-year period. Starting at 2,124 million US dollars in 2020, it declined significantly to 1,084 million in 2021, followed by a moderate increase to 1,368 million in 2022. In the subsequent years, the provision dropped sharply to 400 million in 2023 but experienced a slight rebound to 554 million in 2024. This pattern suggests variability in taxable income or changes in tax strategy or regulations impacting the provision calculation.
Cash Operating Taxes
Cash operating taxes display a different trajectory compared to income tax provisions, indicating potential timing differences or other tax-related factors. The amount nearly doubled from 1,445 million in 2020 to 2,764 million in 2021, followed by a further substantial increase to 4,376 million in 2022. However, in 2023, cash operating taxes declined to 3,947 million and continued to drop to 3,068 million in 2024. Despite the reductions in recent years, cash tax payments remain significantly higher than in 2020. This trend may reflect changes in cash flow management, tax payment scheduling, or adjustments related to tax liabilities and credits.
Overall Insights
The divergence between income tax provision and cash operating taxes is notable. While income tax provisions generally decreased over the period with some volatility, cash operating taxes rose sharply before declining in the last two years but still remained elevated relative to 2020. These contrasting patterns could indicate differences in accounting recognition of tax expenses versus actual cash outflows. The fluctuations in both indicators highlight the importance of analyzing tax-related cash impacts separately from accounting provisions to fully understand the company's tax position and its effect on liquidity and profitability.

Invested Capital

Bristol-Myers Squibb Co., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term debt obligations
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total BMS shareholders’ equity
Net deferred tax (assets) liabilities2
Allowance for expected credit loss3
Restructuring liability4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interest
Adjusted total BMS shareholders’ equity
Construction in progress7
Marketable debt securities and equity investments8
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring liability.

5 Addition of equity equivalents to total BMS shareholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable debt securities and equity investments.


Total reported debt & leases
There is a noticeable reduction in total reported debt and leases from 2020 to 2022, falling from approximately $51.7 billion to about $40.7 billion. However, the debt level stabilizes around $41.5 billion in 2023 before increasing significantly to $51.2 billion in 2024, approaching the 2020 debt level once again.
Total BMS shareholders’ equity
The shareholders’ equity shows a consistent declining trend over the five-year period. Starting at around $37.8 billion in 2020, it decreases gradually each year, falling to roughly $16.3 billion in 2024. This decline is particularly pronounced between 2023 and 2024, where equity drops by nearly 45%, indicating potential challenges impacting the company’s net worth.
Invested capital
Invested capital follows a downward trend over the period, beginning at approximately $90.1 billion in 2020 and decreasing steadily every year to around $62.7 billion in 2024. The continuous reduction suggests contraction in the company's asset base or potential divestitures and may relate to the simultaneously falling equity and fluctuating debt levels.

Cost of Capital

Bristol-Myers Squibb Co., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Bristol-Myers Squibb Co., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The analysis of the financial data over the five-year period reveals significant fluctuations and notable trends in the economic profit, invested capital, and economic spread ratio.

Economic Profit
The economic profit exhibits considerable volatility throughout the years. It starts with a substantial negative value of -13,301 million USD at the end of 2020, indicating a significant economic loss. In 2021, this metric dramatically shifts to a positive 611 million USD, suggesting improved profitability or effective capital utilization. However, the positive trend does not sustain consistently as the economic profit turns negative again in 2022, at -1,119 million USD. The year 2023 sees a recovery back to positive territory with 834 million USD, but this improvement is followed by a sharp decline in 2024, plummeting to -13,985 million USD, the worst value within the five-year span. Such fluctuations indicate unstable economic returns and possibly challenges in maintaining consistent value creation.
Invested Capital
Invested capital shows a clear decreasing trend across the period. It declines steadily from 90,149 million USD at the end of 2020 to 62,654 million USD by the end of 2024. This continuous reduction suggests the company is either divesting assets, optimizing capital structure, or experiencing shrinkage in productive capital base. The nearly 30% decline may have implications on operational scale or efficiency and could be linked to shifts in strategic focus or external market conditions.
Economic Spread Ratio
Economic spread ratio, expressed as a percentage, mirrors the volatility seen in economic profit. It starts very negative at -14.75% in 2020, improves dramatically to a positive 0.76% in 2021, then declines to -1.56% in 2022. The ratio once again improves to 1.23% in 2023 before sharply deteriorating to -22.32% in 2024. This pattern indicates alternating periods of positive and negative returns on invested capital relative to the cost of capital, with the sharp negative value in 2024 possibly reflecting a significant downturn in profitability or increased capital costs.

Overall, the data portrays a company experiencing substantial instability in generating economic value, with declining capital investment and alternating positive and negative returns. The pronounced downturn in 2024 in both economic profit and economic spread ratio is particularly noteworthy and may warrant further investigation into underlying causes, such as operational challenges, market factors, or strategic decisions impacting financial performance.


Economic Profit Margin

Bristol-Myers Squibb Co., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Over the analyzed period, the economic profit of the company exhibits significant volatility. In 2020, a substantial negative economic profit was recorded, indicating losses in economic terms. This was followed by a positive turn in 2021, where economic profit became positive, albeit relatively modest. However, the year 2022 saw a return to negative economic profit, which again improved to a positive figure in 2023 before sharply declining to its most negative point in 2024. This fluctuation suggests variability in the company's ability to generate returns above its cost of capital over time.

Revenues demonstrate moderate fluctuations across the years. After an initial increase from 2020 to 2021, revenues slightly decreased in 2022 and 2023, before rising again in 2024 to the highest value in the observed series. These revenue movements indicate some instability but a general resilience with a recovery trend in the most recent period.

The economic profit margin closely mirrors the trend of economic profit, reinforcing the narrative of inconsistent profitability relative to revenue. The margin shifts from a deep negative in 2020 to slightly positive in 2021, dips to negative again in 2022, recovers in 2023, and then plunges to a notably negative level in 2024. This pattern highlights challenges in maintaining profitability efficiency despite relatively stable revenue figures.

Summary
The company experienced marked inconsistency in generating economic profit over the five-year span, reflected in swings between losses and small profits. Revenues showed some growth but lacked a steady upward trajectory. Profitability margins as a percentage of revenue followed a similar unstable pattern, underscoring difficulties in sustaining effective profit generation despite revenue growth in the final year.